Table 4.
Details of the currently recruiting trials on melatonin.
| Conditions | Number Patients | Treatment | Duration (Days) (Years) | Observational | |
|---|---|---|---|---|---|
| Smith-Magenis syndrome | 8 | 1 | Mel measure | NCT02180451 | |
| Autism | 105 | 3 | Mel measure | NCT02878499 | |
| Cushing disease | 15 | 90 | Mel measure | NCT03343470 | |
| Breast Neoplasms | 27 | 270 | Mel measure | NCT04364347 | |
| Alzheimer’s Disease | 60 | * | Mel measure | NCT04522960 | |
| Sleep deprivation | 20 | 32 | Mel measure | NCT04868539 | |
| Frail Elderly | 300 | 3 | Mel measure | NCT05107947 | |
| Hypo-hidrotic Ectodermal Dysplasia | 80 | 10 | Mel measure | NCT05378932 | |
| Bipolar disorder | 80 | 2 | Mel measure | NCT05413486 | |
| Alzheimer’s Disease | 164 | 42 | Mel measure | NCT05543681 | |
| Sleep Disturbance | 60 | 3 | Mel measure | NCT05647148 | |
| Hypoxic-ischemic Encephalopathy | 70 | 0.5–5 mg | 14 | NCT02621944 | |
| Delirium | 190 | 4 mg | 28 | NCT03438526 | |
| Multiple Progressive Primary Sclerosis | 50 | 100 mg daily | 2 | NCT03540485 | |
| Alzheimer’s Disease | 230 | 5 mg daily | 231 | NCT03954899 | |
| Osteopenia | 40 | 5 mg daily | 1 | NCT04233112 | |
| Attention Deficit Hyperactivity Disorder | 80 | 3 mg daily | 0.5 | NCT04318067 | |
| Postoperative delirium | 790 | 4 mg daily | 10 | NCT04335968 | |
| Huntington’s Disease | 20 | 5 mg daily | 63 | NCT04421339 | |
| COVID-19 infection | 30 | 3 × 10 mg daily | 28 | NCT04474483 | |
| Diabetic Eye Problems | 36 | 3 mg daily | 14 | NCT04547439 | |
| Post-operative pain | 60 | 10 mg 3 days | 21 | NCT04791943 | |
| Osteoarthritis | 252 | 5 mg daily | 60 | NCT04795336 | |
| Traumatic Brain Injury | 110 | 3–5 mg daily | 30 | NCT04932096 | |
| Necrotizing Enterocolitis | 100 | 6 mg daily | 150 | NCT05033639 | |
| Emergence Agitation | 117 | 5 mg pre-op *** | 1 | NCT05223010 | |
| Ischemic Stroke | 80 | 3 mg daily | 14 | NCT05247125 | |
| Hypertension | 23 | 1 mg daily | 1 | NCT05257291 | |
| PD | 50 | 5 mg daily | 28 | NCT05307770 | |
| Epilepsy | 120 | 5 mg daily | 28 | NCT05439876 | |
| Post-menopause insomnia | 14 | 2 mg daily | 15 | NCT05440734 | |
| Chronic Fatigue Syndrome | 106 | 1 mg daily | 28 | NCT05454683 | |
| Uveal Melanoma | 100 | 20 mg daily | 5 | NCT05502900 | |
| Severe Preterm Fetal Growth Restriction | 336 | 3 × 10 mg daily ** | 126 | NCT05651347 | |
* From 2 days to 2 years. ** Treatment to the mother, not clearly stating for how many days.*** Pre-op means pre-operation.